
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES105
The extended HOPE trial identified that at the end of the extension phase there was a significant
further reduction in risk for diabetes for ramipril vs placebo (2.7% vs 4.0%, RR 0.66, 0.46 to
0.95).241 Level 1+

[@Casas_2005]

